3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
9
Urinary Bladder Neoplasms
7
Ureteral Neoplasms
3
Muscle Invasive Bladder Urothelial Carcinoma
2
Carcinoma, Renal Cell
2
Advanced Bladder Cancer
2
Urogenital Neoplasms
1
Urachal adenocarcinoma
1
Salivary Gland Neoplasms
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Penile Squamous Cell Carcinoma (PSCC)
1
Penile Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Melanoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma, Adenoid Cystic
1
Interventions
padeliporfin
5
Nivolumab
3
vedolizumab
2
atezolizumab
2
anlotinib
2
Therapeutics
2
Surveys and Questionnaires
2
Riluzole
2
Radiotherapy
2
LDP-02
2
Ipilimumab
2
Infliximab
2
Immunoglobulin G
2
Genetic Testing
2
Fecal Microbiota Transplantation
2
Disulfides
2
Carboplatin
2
CT-P13
2
tislelizumab
1
relatlimab
1
prednylidene
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
ixabepilone
1
ferumoxtran-10
1
enfortumab vedotin
1
deltacortene
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urogenital Neoplasms
×
enfortumab vedotin
×
Clear all
NCT06724159
2026-02-17
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
Recruiting
500 enrolled